

# Carlos Alves

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8528600/publications.pdf>

Version: 2024-02-01

50  
papers

960  
citations

471509

17  
h-index

454955

30  
g-index

51  
all docs

51  
docs citations

51  
times ranked

1556  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Risk of Infections Associated With JAK Inhibitors in Rheumatoid Arthritis. <i>Journal of Clinical Rheumatology</i> , 2022, 28, e407-e414.	0.9	20
2	Risk of Cardiovascular and Venous Thromboembolic Events Associated With Janus Kinase Inhibitors in Rheumatoid Arthritis. <i>Journal of Clinical Rheumatology</i> , 2022, 28, 69-76.	0.9	16
3	Real-world intensive safety monitoring of biosimilars rituximab and trastuzumab in a Portuguese oncology hospital. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 1432-1438.	0.9	6
4	Outcomes From the First 6 Years of Operation of the Central Portugal Pharmacovigilance Unit. <i>Journal of Patient Safety</i> , 2020, 16, e136-e142.	1.7	1
5	Intensive safety monitoring program of antineoplastic medicines: A pilot study in a Portuguese oncology hospital. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 133-140.	0.9	1
6	Risk of nonarteritic ischaemic optic neuropathy with phosphodiesterase type 5 inhibitors: a systematic review and meta-analysis. <i>Acta Ophthalmologica</i> , 2020, 98, 22-31.	1.1	7
7	A Systematic Review of Economic Studies Evaluating Ophthalmic Drugs: An Analysis of the Health-state Utilities. <i>Ophthalmic Epidemiology</i> , 2020, 27, 325-338.	1.7	1
8	Rectus sheath hematoma in patients receiving subcutaneous enoxaparin: A case series of five patients. <i>Clinical Case Reports (discontinued)</i> , 2020, 8, 3431-3438.	0.5	4
9	Spontaneous reports of hypersensitivity adverse drug reactions in Portugal: a retrospective analysis. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 763-769.	2.4	3
10	An analysis of the effectiveness outcomes of economic studies evaluating ophthalmic drugs: a systematic review. <i>Acta Ophthalmologica</i> , 2020, 98, 237-243.	1.1	0
11	Risk of infections and cardiovascular and venous thromboembolic events associated with JAK inhibitors in rheumatoid arthritis: protocols of two systematic reviews and network meta-analyses. <i>BMJ Open</i> , 2020, 10, e041420.	1.9	3
12	Risk of infections and cardiovascular and venous thromboembolic events associated with JAK inhibitors in rheumatoid arthritis: protocols of two systematic reviews and network meta-analyses. <i>BMJ Open</i> , 2020, 10, e041420.	1.9	3
13	Drug-induced hypersensitivity: A 5-year retrospective study in a hospital electronic health records database. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2019, 44, 54-61.	1.5	6
14	Fluoroquinolones and the risk of tendon injury: a systematic review and meta-analysis. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 1431-1443.	1.9	66
15	Prevalence of Undiagnosed Hypothyroidism in Europe: A Systematic Review and Meta-Analysis. <i>European Thyroid Journal</i> , 2019, 8, 130-143.	2.4	63
16	A systematic review of the methodological quality of economic studies evaluating ophthalmic drugs. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019, 19, 421-430.	1.4	5
17	Effectiveness in clinical practice versus efficacy of dipeptidyl peptidase-4 inhibitors in clinical trials for type 2 diabetes: protocol for systematic review. <i>BMJ Open</i> , 2019, 9, e032522.	1.9	0
18	A comparison between two recommendations to conduct and report systematic reviews on drug safety. <i>Systematic Reviews</i> , 2019, 8, 238.	5.3	1

#	ARTICLE	IF	CITATIONS
19	Recommendations to conduct and report systematic reviews in medical literature: a scoping review. BMC Medical Research Methodology, 2019, 19, 234.	3.1	5
20	PSS37 - A SYSTEMATIC REVIEW OF THE METHODOLOGICAL QUALITY OF ECONOMIC STUDIES EVALUATING OPHTHALMIC DRUGS. Value in Health, 2018, 21, S429.	0.3	0
21	PRM273 - METHODOLOGICAL CONSIDERATIONS ON THE RECOMMENDATIONS TO CONDUCT AND REPORT SYSTEMATIC REVIEWS IN MEDICAL LITERATURE: SYSTEMATIC REVIEW. Value in Health, 2018, 21, S403.	0.3	2
22	Statins and risk of cataracts: A systematic review and meta-analysis of observational studies. Cardiovascular Therapeutics, 2018, 36, e12480.	2.5	14
23	Number needed to treat (NNT) in clinical literature: an appraisal. BMC Medicine, 2017, 15, 112.	5.5	106
24	The Use of the Number Needed to Treat (NNT) to Assess the Effects of Medicinal Interventions: A Quality Assessment. Clinical Therapeutics, 2017, 39, e39-e40.	2.5	0
25	Risk of Ophthalmic Adverse Effects in Patients Treated with MEK Inhibitors: A Systematic Review and Meta-Analysis. Ophthalmic Research, 2017, 57, 60-69.	1.9	14
26	A systematic review of observational studies evaluating costs of adverse drug reactions. ClinicoEconomics and Outcomes Research, 2016, Volume 8, 413-426.	1.9	41
27	Testing the usefulness of the number needed to treat to be harmed (NNTH) in benefit-risk evaluations: case study with medicines withdrawn from the European market due to safety reasons. Expert Opinion on Drug Safety, 2016, 15, 1301-1312.	2.4	13
28	Benefit-Risk of Therapies for Relapsing-Remitting Multiple Sclerosis: Testing the Number Needed to Treat to Benefit (NNTB), Number Needed to Treat to Harm (NNTH) and the Likelihood to be Helped or Harmed (LHH): A Systematic Review and Meta-Analysis. CNS Drugs, 2016, 30, 909-929.	5.9	21
29	A systematic review and meta-analysis of the association between systemic fluoroquinolones and retinal detachment. Acta Ophthalmologica, 2016, 94, e251-9.	1.1	16
30	Drug Transport Across Blood-Ocular Barriers and Pharmacokinetics. , 2016, , 37-63.		5
31	Number needed to harm in the post-marketing safety evaluation: results for rosiglitazone and pioglitazone. Pharmacoepidemiology and Drug Safety, 2015, 24, 1259-1270.	1.9	20
32	Farmacovigilância em Portugal: Atividade da Unidade Regional do Centro. Acta Medica Portuguesa, 2015, 28, 222-232.	0.4	13
33	The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer - a systematic review. Breast Cancer Research, 2015, 17, 140.	5.0	143
34	Ocular adverse events induced by Drugs: a review of the safety alerts issued by Health Regulatory Authorities. Clinical Therapeutics, 2015, 37, e122-e123.	2.5	0
35	Drug-Induced Ocular Adverse Reactions: Review of the Safety Alerts Issued During the Last Decade. Journal of Ocular Pharmacology and Therapeutics, 2015, 31, 258-268.	1.4	12
36	The efficacy and safety of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: a systematic review and meta-analysis. Clinical Therapeutics, 2015, 37, e123-e124.	2.5	1

#	ARTICLE	IF	CITATIONS
37	Costs of Adverse Drug Events: Systematic Review. <i>Value in Health</i> , 2015, 18, A517.	0.3	1
38	The Role of Disproportionality Analysis of Pharmacovigilance Databases in Safety Regulatory Actions: a Systematic Review. <i>Current Drug Safety</i> , 2015, 10, 234-250.	0.6	23
39	Safety profiles of adalimumab, etanercept and infliximab: a pharmacovigilance study using a measure of disproportionality in a database of spontaneously reported adverse events. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2014, 39, 307-313.	1.5	20
40	The Benefit of Her-2 Targeted Therapies on Overall Survival of Patients With Metastatic Breast Cancer – A Systematic Review. <i>Value in Health</i> , 2014, 17, A620.	0.3	1
41	Nurses' spontaneous reporting of adverse drug reactions: expert review of routine reports. <i>Journal of Nursing Management</i> , 2014, 22, 322-330.	3.4	18
42	Drug-safety alerts issued by regulatory authorities: usefulness of meta-analysis in predicting risks earlier. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 745-756.	1.9	10
43	Safety Monitoring of Ophthalmic Biologics: A Systematic Review of Pre- and Postmarketing Safety Data. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2014, 30, 729-751.	1.4	19
44	Sources of information used by regulatory agencies on the generation of drug safety alerts. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 2083-2094.	1.9	27
45	Safety of biologics approved for treating rheumatoid arthritis: analysis of spontaneous reports of adverse events. <i>Clinical Rheumatology</i> , 2013, 32, 1207-1214.	2.2	10
46	Apixaban and Rivaroxaban Safety After Hip and Knee Arthroplasty. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2012, 17, 266-276.	2.0	20
47	A meta-analysis of serious adverse events reported with exenatide and liraglutide: Acute pancreatitis and cancer. <i>Diabetes Research and Clinical Practice</i> , 2012, 98, 271-284.	2.8	135
48	Data sources on drug safety evaluation: a review of recent published meta-analyses. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 21-33.	1.9	17
49	Intoxicação grave desconhecida, notificações e notificadores: Resultados da actividade da Unidade de Farmacovigilância do Centro. <i>Revista Portuguesa De Clínica Geral</i> , 2012, 28, 34-40.	0.0	1
50	Multiple drug exposure as a risk factor for the seriousness of adverse drug reactions. <i>Journal of Nursing Management</i> , 2011, 19, 395-399.	3.4	21